Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Top Cited Papers
Open Access
- 1 August 2006
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 10 (2), 159-170
- https://doi.org/10.1016/j.ccr.2006.07.003
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKBMolecular Cell, 2006
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates AktCancer Research, 2006
- Akt1/protein kinase B is critical for ischemic and VEGF-mediated angiogenesisJournal of Clinical Investigation, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)Science, 2001
- Glomeruloid Microvascular Proliferation Follows Adenoviral Vascular Permeability Factor/Vascular Endothelial Growth Factor-164 Gene DeliveryThe American Journal of Pathology, 2001
- Different Pathways of Macromolecule Extravasation from Hyperpermeable Tumor VesselsMicrovascular Research, 2000
- Pathways of Macromolecular Extravasation Across Microvascular Endothelium in Response to VPF/VEGF and Other Vasoactive MediatorsMicrocirculation, 1999